Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.43 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.43 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597578 | 0.89 | IDO1 (0.52) | EPHX2CYP4A11CYP4F2IDO1 | |
| SCHEMBL22921868 | 0.89 | TSHR (0.58) | EPHX2TSHRCYP4A11CYP4F2ALOX5 | |
| SCHEMBL6535275 | 0.83 | EPHX2 (0.57) | EPHX2TSHRL3MBTL1 | |
| SCHEMBL13768703 | 0.82 | POLB (0.50) | NPC1RAB9A | |
| SCHEMBL28693818 | 0.82 | KDM1A (0.44) | NPC1RAB9A | |
| SCHEMBL17087191 | 0.82 | HSD17B10 (0.61) | EPHX2TSHR | |
| SCHEMBL1863579 | 0.82 | CALM1 (0.55) | EPHX2TSHRCYP4A11CYP4F2 | |
| SCHEMBL1866015 | 0.82 | CYP4A11 (0.50) | EPHX2TSHRCYP4A11CYP4F2ALOX5 | |
| SCHEMBL12508639 | 0.82 | TSHR (0.50) | EPHX2TSHRCYP4A11CYP4F2ALOX5 | |
| SCHEMBL3456495 | 0.82 | CYP4A11 (0.53) | EPHX2TSHRCYP4A11CYP4F2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| WO-1996004246-A1 | PHENYLACETAMIDES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273842-A1 | AMINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | NPY5R, NPY1R, NPY2R | EPHX2 2265/4885TSHR 153/4885CYP4A11 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.